{"product_id":"global-female-infertility-treatment-drugs-market-size-study-forecast-by-therapy-gonadotropins-clomiphene-letrozole-metformin-leuprolide-acetate-and-others-by-route-of-administration-oral-and-injectable-by-distribution-channel-hospitals-pha","title":"Global Female Infertility Treatment Drugs  Market Size study \u0026 Forecast, by Therapy( Gonadotropins, Clomiphene, Letrozole, Metformin , Leuprolide Acetate and Others) by Route of Administration( Oral and Injectable), by Distribution Channel ( Hospitals Pha","description":"\u003cp\u003eGlobal Female Infertility Treatment Drugs  Market Size study \u0026amp; Forecast, by Therapy( Gonadotropins, Clomiphene, Letrozole, Metformin , Leuprolide Acetate and Others) by Route of Administration( Oral and Injectable), by Distribution Channel ( Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal Female Infertility Treatment Drugs  Market is valued approximately USD 2,649.8 million in 2021 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2022-2029. Female infertility is a condition where a woman is unable to conceive. Female infertility can be caused by several variables, including age, hormonal imbalance, physical health, and lifestyle choices. A few of the tests used to identify female infertility include ovarian reserve testing, hysterosalpingography, and ovulation testing. The Female Infertility Treatment Drugs  market is expanding because of factors such as increasing infertility rates globally and increasing funding for infertility R\u0026amp;D. However, the presence of effective alternatives to medication, high cost of drugs may halt market growth.\u003c\/p\u003e\n\n\u003cp\u003eDecline in prevalence of fertility rates across the globe is fostering the market growth. For instance, according to the World Bank Organisation, the total fertility rate (births per woman) was 2.427 in 2017, which was further decreased to 2.402 in 2019, globally. Thus these decline indicates the rise in infertility rates which is driving the marker growth. Furthermore, Governments worldwide to support to infertility patients by providing insurance coverage for treatment and rise in drug development activities is creating a lucrative growth to the market.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Female Infertility Treatment Drugs  Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing infertility rate. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nFerring Pharmaceuticals\u003cbr\u003e\nMerck \u0026amp; Co, Inc.\u003cbr\u003e\nBayer AG\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nPar Pharmaceuticals\u003cbr\u003e\nSumitovant\u003cbr\u003e\nLivzon\u003cbr\u003e\nZydus Cadila\u003cbr\u003e\nMankind Pharma\u003cbr\u003e\nOxolife\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In January 2020, Bayer AG announced a new five-year, multi-target collaboration with Evotec SE, a biotechnology company specialising in women's health, to develop a number of clinical candidates for the treatment of polycystic ovarian syndrome (PCOS), one of the factors contributing to female infertility.\u003cbr\u003e\n? In January 2019, Ferring Pharmaceuticals, a biopharmaceutical company, signed an exclusive agreement with Sun Pharmaceutical Industries Ltd., an Indian multinational pharmaceutical company, to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate Injection, which is used to treat female infertility.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Female Infertility Treatment Drugs  Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Therapy, Route of Administration, Distribution Channel, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Therapyofferings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Therapy:\u003cbr\u003e\nGonadotropins\u003cbr\u003e\nClomiphene\u003cbr\u003e\nLetrozole\u003cbr\u003e\nMetformin\u003cbr\u003e\nLeuprolide Acetate\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Route of Administration:\u003cbr\u003e\nOral\u003cbr\u003e\nInjectable\u003cbr\u003e\nBy Distribution Channel:\u003cbr\u003e\nHospitals Pharmacies\u003cbr\u003e\nRetail Pharmacies\u003cbr\u003e\nOnline Pharmacies\u003cbr\u003e\nBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eFerring Pharmaceuticals\u003cbr\u003e\nMerck \u0026amp; Co, Inc.\u003cbr\u003e\nBayer AG\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nPar Pharmaceuticals\u003cbr\u003e\nSumitovant\u003cbr\u003e\nLivzon\u003cbr\u003e\nZydus Cadila\u003cbr\u003e\nMankind Pharma\u003cbr\u003e\nOxolife\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"March, 2023 \/ 200 Pages \/ MCW16240583","offer_id":47657613033778,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-female-infertility-treatment-drugs-market-size-study-forecast-by-therapy-gonadotropins-clomiphene-letrozole-metformin-leuprolide-acetate-and-others-by-route-of-administration-oral-and-injectable-by-distribution-channel-hospitals-pha","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}